638 related articles for article (PubMed ID: 8610716)
1. Addition of anticholinergic solution prolongs bronchodilator effect of beta 2 agonists in patients with chronic obstructive pulmonary disease.
Levin DC; Little KS; Laughlin KR; Galbraith JM; Gustman PM; Murphy D; Kram JA; Hardie G; Reuter C; Ostransky D; McFarland K; Petty TL; Silvers W; Rennard SI; Mueller M; Repsher LH; Zuwallack RL; Vale R
Am J Med; 1996 Jan; 100(1A):40S-48S. PubMed ID: 8610716
[TBL] [Abstract][Full Text] [Related]
2. A multicenter study of nebulized bronchodilator solutions in chronic obstructive pulmonary disease.
Friedman M
Am J Med; 1996 Jan; 100(1A):30S-39S. PubMed ID: 8610715
[TBL] [Abstract][Full Text] [Related]
3. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
[TBL] [Abstract][Full Text] [Related]
4. Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease.
Colice GL
Am J Med; 1996 Jan; 100(1A):11S-18S. PubMed ID: 8610712
[TBL] [Abstract][Full Text] [Related]
5. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.
Jarvis B; Markham A
Drugs Aging; 2001; 18(6):441-72. PubMed ID: 11419918
[TBL] [Abstract][Full Text] [Related]
6. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group.
Chest; 1994 May; 105(5):1411-9. PubMed ID: 8181328
[TBL] [Abstract][Full Text] [Related]
7. Anticholinergic versus beta 2-agonist on gas exchange in COPD: a comparative study in 15 patients.
Pillet O; Manier G; Castaing Y
Monaldi Arch Chest Dis; 1998 Feb; 53(1):3-8. PubMed ID: 9632900
[TBL] [Abstract][Full Text] [Related]
8. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group.
Maesen FP; Smeets JJ; Sledsens TJ; Wald FD; Cornelissen PJ
Eur Respir J; 1995 Sep; 8(9):1506-13. PubMed ID: 8575576
[TBL] [Abstract][Full Text] [Related]
9. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base.
Campbell S
Arch Intern Med; 1999 Jan; 159(2):156-60. PubMed ID: 9927098
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial.
Donohue JF; Wise R; Busse WW; Garfinkel S; Zubek VB; Ghafouri M; Manuel RC; Schlenker-Herceg R; Bleecker ER
BMC Pulm Med; 2016 Apr; 16(1):65. PubMed ID: 27130202
[TBL] [Abstract][Full Text] [Related]
11. [A comparison of bronchodilating drugs in the treatment of stable COPD].
Nishimura K; Koyama H; Izumi T
Nihon Kyobu Shikkan Gakkai Zasshi; 1992 May; 30(5):835-43. PubMed ID: 1385837
[TBL] [Abstract][Full Text] [Related]
12. A comparison of ipratropium and albuterol vs albuterol alone for the treatment of acute asthma.
Karpel JP; Schacter EN; Fanta C; Levey D; Spiro P; Aldrich T; Menjoge SS; Witek TJ
Chest; 1996 Sep; 110(3):611-6. PubMed ID: 8797400
[TBL] [Abstract][Full Text] [Related]
13. Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease.
Tsukino M; Nishimura K; Ikeda A; Hajiro T; Koyama H; Izumi T
Thorax; 1998 Apr; 53(4):269-73. PubMed ID: 9741369
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD.
Friedman M; Serby CW; Menjoge SS; Wilson JD; Hilleman DE; Witek TJ
Chest; 1999 Mar; 115(3):635-41. PubMed ID: 10084468
[TBL] [Abstract][Full Text] [Related]
15. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group.
Gross N; Tashkin D; Miller R; Oren J; Coleman W; Linberg S
Respiration; 1998; 65(5):354-62. PubMed ID: 9782217
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.
Quinn D; Barnes CN; Yates W; Bourdet DL; Moran EJ; Potgieter P; Nicholls A; Haumann B; Singh D
Pulm Pharmacol Ther; 2018 Feb; 48():71-79. PubMed ID: 28987804
[TBL] [Abstract][Full Text] [Related]
17. Daily variation in lung function in COPD patients with combined albuterol and ipratropium: results from a 4-week, randomized, crossover study.
Singh D; Zhu CQ; Sharma S; Church A; Kalberg CJ
Pulm Pharmacol Ther; 2015 Apr; 31():85-91. PubMed ID: 25197005
[TBL] [Abstract][Full Text] [Related]
18. Comparison of ipratropium bromide and albuterol in chronic obstructive pulmonary disease: a three-center study.
Braun SR; Levy SF
Am J Med; 1991 Oct; 91(4A):28S-32S. PubMed ID: 1835292
[TBL] [Abstract][Full Text] [Related]
19. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD: comparison with ipratropium bromide alone.
Ikeda A; Nishimura K; Koyama H; Izumi T
Chest; 1995 Feb; 107(2):401-5. PubMed ID: 7842768
[TBL] [Abstract][Full Text] [Related]
20. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease.
Rennard SI; Anderson W; ZuWallack R; Broughton J; Bailey W; Friedman M; Wisniewski M; Rickard K
Am J Respir Crit Care Med; 2001 Apr; 163(5):1087-92. PubMed ID: 11316640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
